FDA Approves First Pill to Treat C. difficile Infections

The FDA on Wednesday approved the first pill form of fecal microbiota -- similar to what's known as fecal transplant therapy -- to treat the bacterial infection Clostridioides difficile, one of the most common and deadly infections found in health care settings. The drug, Vowst, is approved to prevent recurrence of C. difficile in people who have already had standard antibacterial treatment for recurrent infection. It contains live gut bacteria from stool samples donated by healthy people. The dosing regimen of Vowst is four capsules taken once a day, orally, for three consecutive days. Vowst contains live bacteria and is manufactured from human fecal matter that has been donated by qualified individuals. Read more from the FDA here.